Contrast enhancement in magnetic resonance imaging for assessment of central nervous system pathology research hub

(21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs)

This study is testing a new, lower-dose contrast dye called gadoquatrane for MRI brain scans. It wants to see if it's as good and safe as current higher-dose dyes at showing problems in the brain and spinal cord, like tumours or inflammation.